keyword
MENU ▼
Read by QxMD icon Read
search

Free psa

keyword
https://www.readbyqxmd.com/read/28820987/a-new-label-free-electrochemical-immunosensor-based-on-dendritic-core-shell-aupd-au-nanocrystals-for-highly-sensitive-detection-of-prostate-specific-antigen
#1
Rui Wang, Wei-Dong Liu, Ai-Jun Wang, Yadong Xue, Liang Wu, Jiu-Ju Feng
Herein, bimetallic dendritic core-shell AuPd@Au nanocrystals (AuPd@Au NCs) were prepared by a simple one-pot aqueous method using xanthine as a green growth-directing agent. By virtue of the enhanced peak currents in the H2O2 reduction catalyzed by AuPd@Au NCs, a label-free immunosensor was constructed for the detection of prostate specific antigen (PSA). The immunosensor exhibited significantly improved analytical performance for the assay of PSA with wide linear range of 0.1-50ngmL(-1) and low detection limit of 0...
August 10, 2017: Biosensors & Bioelectronics
https://www.readbyqxmd.com/read/28819719/activity-of-cabazitaxel-in-patients-with-metastatic-castration-resistant-prostate-cancer-after-treatment-with-single-or-dual-regimens-of-novel-androgen-receptor-targeting-agents
#2
Yukari Bando, Nobuyuki Hinata, Tomoaki Terakawa, Junya Furukawa, Ken-Ichi Harada, Yuzo Nakano, Masato Fujisawa
The purpose of this study was to evaluate the efficacy of cabazitaxel for patients with metastatic castration-resistant prostate cancer (mCRPC) after sequential therapy with docetaxel (DTX) and single or dual regimens of novel androgen receptor-axis-targeted (ARAT) agents. We retrospectively reviewed 84 consecutive patients treated with cabazitaxel at Kobe University Hospital and related hospitals from September 2014 to September 2016. The association of each prognostic parameter with progression-free survival (PFS) was evaluated, including the sequence of therapy...
August 17, 2017: Medical Oncology
https://www.readbyqxmd.com/read/28818527/prostate-specific-antigen-testing-after-radical-prostatectomy-can-we-stop-at-20-years
#3
Wesley W Ludwig, Zhaoyong Feng, Bruce J Trock, Elizabeth Humphreys, Patrick C Walsh
PURPOSE: To examine the clinical features and outcomes associated with delayed biochemical recurrence after radical prostatectomy, specifically amongst men with over 20 years of follow-up. MATERIALS AND METHODS: 16,720 men underwent radical prostatectomy and 2,699 experienced biochemical recurrence. We determined predictors of delayed biochemical recurrence as well as metastasis-free survival and cancer specific survival rates for recurrence at various time points after radical prostatectomy...
August 14, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28818355/ar-v7-in-peripheral-whole-blood-of-patients-with-castration-resistant-prostate-cancer-association-with-treatment-specific-outcome-under-abiraterone-and-enzalutamide
#4
Anna Katharina Seitz, Silvia Thoene, Andreas Bietenbeck, Roman Nawroth, Robert Tauber, Mark Thalgott, Sebastian Schmid, Ramona Secci, Margitta Retz, Jürgen E Gschwend, Jürgen Ruland, Christof Winter, Matthias M Heck
BACKGROUND: It has been demonstrated that androgen receptor splice variant 7 (AR-V7) expression in circulating tumor cells (CTCs) predicts poor treatment response in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone or enzalutamide. OBJECTIVE: To develop a practical and robust liquid profiling approach for direct quantification of AR-V7 in peripheral whole blood without the need for CTC capture and to determine its potential for predicting treatment response in mCRPC patients...
August 14, 2017: European Urology
https://www.readbyqxmd.com/read/28815018/serum-complexed-and-free-prostate-specific-antigen-levels-are-lower-in-female-elite-athletes-in-comparison-to-control-women
#5
Emma Eklund, Eleftherios P Diamandis, Carla Muytjens, Sarah Wheeler, Anu Mathew, Martin Stengelin, Eli Glezer, Galina Nikolenko, Marshall D Brown, Yingye Zheng, Angelica Lindén Hirschberg
BACKGROUND: We hypothesize that prostate specific antigen (PSA), a protein that it is under regulation by androgens, may be differentially expressed in female elite athletes in comparison to control women. METHODS: We conducted a cross-sectional study of 106 female athletes and 114 sedentary age-matched controls.  Serum from these women was analyzed for complexed prostate specific antigen (cPSA) and free prostate specific antigen (fPSA), by fifth generation assays with limits of detection of around 6 and 140 fg/mL, respectively...
2017: F1000Research
https://www.readbyqxmd.com/read/28811062/validation-of-the-prostate-health-index-in-a-predictive-model-of-prostate-cancer
#6
A Sanchís-Bonet, M Barrionuevo-González, A M Bajo-Chueca, L Pulido-Fonseca, L E Ortega-Polledo, J C Tamayo-Ruiz, M Sánchez-Chapado
OBJECTIVES: To validate and analyse the clinical usefulness of a predictive model of prostate cancer that incorporates the biomarker «[-2] pro prostate-specific antigen» using the prostate health index (PHI) in decision making for performing prostate biopsies. MATERIAL AND METHODS: We isolated serum from 197 men with an indication for prostate biopsy to determine the total prostate-specific antigen (tPSA), the free PSA fraction (fPSA) and the [-2] proPSA (p2PSA)...
August 12, 2017: Actas Urologicas Españolas
https://www.readbyqxmd.com/read/28809610/phase-iii-study-comparing-a-reduced-dose-of-cabazitaxel-20-mg-m-2-and-the-currently-approved-dose-25-mg-m-2-in-postdocetaxel-patients-with-metastatic-castration-resistant-prostate-cancer-proselica
#7
Mario Eisenberger, Anne-Claire Hardy-Bessard, Choung Soo Kim, Lajos Géczi, Daniel Ford, Loïc Mourey, Joan Carles, Phillip Parente, Albert Font, Gabriel Kacso, Mustapha Chadjaa, Wenping Zhang, John Bernard, Johann de Bono
Purpose Cabazitaxel 25 mg/m(2) (C25) significantly improved overall survival (OS) versus mitoxantrone ( P < .001) in postdocetaxel patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase III TROPIC study. The phase III PROSELICA study ( ClinicalTrials.gov identifier: NCT01308580) assessed the noninferiority of cabazitaxel 20 mg/m(2) (C20) versus C25 in postdocetaxel patients with mCRPC. Methods Patients were stratified by Eastern Cooperative Oncology Group performance status, measurability of disease per Response Evaluation Criteria in Solid Tumors (RECIST), and region, and randomly assigned to receive C20 or C25...
August 15, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28807747/pretreatment-3t-multiparametric-mri-staging-predicts-for-biochemical-failure-in-high-risk-prostate-cancer-treated-with-combination-high-dose-rate-brachytherapy-and-external-beam-radiotherapy
#8
John V Hegde, D Jeffrey Demanes, Darlene Veruttipong, Jagdeep Raince, Sang-June Park, Steven S Raman, Nicholas G Nickols, Christopher R King, Amar U Kishan, Michael L Steinberg, Mitchell Kamrava
PURPOSE: To determine whether pretreatment 3T multiparametric MRI (mpMRI) staging impacts biochemical recurrence-free survival (BRFS) or distant metastasis-free survival (DMFS) for men with high-risk prostate cancer treated with combination high-dose-rate (HDR) brachytherapy and external beam radiation therapy (EBRT). MATERIALS AND METHODS: This institutional review board-approved retrospective study included a cohort of 37 men with high-risk prostate cancer treated with HDR brachytherapy and EBRT after 3T mpMRI...
August 11, 2017: Brachytherapy
https://www.readbyqxmd.com/read/28807532/multicenter-evaluation-of-biochemical-relapse-free-survival-outcomes-for-intraoperatively-planned-prostate-brachytherapy-using-an-automated-delivery-system
#9
Kevin Martell, Siraj Husain, Daniel Taussky, Steve Angyalfi, Guila Delouya, Philippe Després, Luc Beaulieu, Andre-Guy Martin, Eric Vigneault
PURPOSE: To report biochemical recurrence in prostate cancer treated with intraoperatively planned low-dose-rate prostate brachytherapy using an automated delivery system (IO-LDRB). METHODS AND MATERIALS: Between 2003 and 2013, 2608 patients from 3 centers were treated with IO-LDRB as single-modality treatment for low or low-tier intermediate-risk prostate cancer. Databases from the 3 centers have been analyzed. These independent databases were collected prospectively...
June 6, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28805047/outcomes-of-post-prostatectomy-radiotherapy-at-a-regional-cancer-centre
#10
Luke Nicholls, Amber Winter, Ashley Harwood, Ashley Plank, Preeti Bagga, Winnie Wong, Eric Khoo
INTRODUCTION: To investigate the efficacy and toxicity of radiation therapy (RT) after radical prostatectomy (RP) for prostate cancer at Radiation Oncology Centres, Toowoomba. METHODS: The electronic medical records of 130 consecutive patients with histologically proven prostate adenocarcinoma who underwent post-prostatectomy RT between January 2008 and December 2014 were analysed. Primary endpoint was Biochemical Recurrence (BCR) after RT. BCR was defined by PSA > 0...
August 14, 2017: Journal of Medical Radiation Sciences
https://www.readbyqxmd.com/read/28804579/validity-of-prostate-health-index-and-percentage-of-2-pro-prostate-specific-antigen-as-novel-biomarkers-in-the-diagnosis-of-prostate-cancer-omani-tertiary-hospitals-experience
#11
Safana S Al Saidi, Nafila B Al Riyami, Mohammed S Al Marhoon, Mohammed S Al Saraf, Salim S Al Busaidi, Riad Bayoumi, Waad-Allah S Mula-Abed
OBJECTIVES: Prostate cancer is the leading cancer in older men. The Ministry of Health Oman Cancer Incidence Registry 2013 lists cancer of the prostate as the first most common cancer in males. Therefore, early detection is important and prostate-specific antigen (PSA) is widely used as an established laboratory test. However, despite its wide use, its value in screening, particularly in asymptomatic males, is controversial when considering the risks and benefits of early detection. METHODS: This prospective, observational study included 136 males (67...
July 2017: Oman Medical Journal
https://www.readbyqxmd.com/read/28803925/impact-of-prostatic-specific-antigen-threshold-and-screening-interval-in-prostate-cancer-screening-outcomes-comparing-the-swedish-and-finnish-european-randomised-study-of-screening-for-prostate-cancer-centres
#12
Lasse Saarimäki, Jonas Hugosson, Teuvo L Tammela, Sigrid Carlsson, Kirsi Talala, Anssi Auvinen
BACKGROUND: The European Randomised Study of Screening for Prostate Cancer trial has shown a 21% reduction in prostate cancer (PC) mortality with prostate-specific antigen (PSA)-based screening. Sweden used a 2-yr screening interval and showed a larger mortality reduction than Finland with a 4-yr interval and higher PSA cut-off. OBJECTIVE: To evaluate the impact of screening interval and PSA cut-off on PC detection and mortality. DESIGN, SETTING, AND PARTICIPANTS: We analysed the core age groups (55-69 yr at entry) of the Finnish (N=31 866) and Swedish (N=5901) screening arms at 13 yr and 16 yr of follow-up...
August 10, 2017: European Urology Focus
https://www.readbyqxmd.com/read/28801291/-value-of-pi-rads-v2-scores-combined-with-prostate-specific-antigen-in-diagnosis-of-peripheral-zone-prostate-cancer-a-logistic-regression-analysis
#13
Li-Zhi Lei, Yi-Kai Xu, Mei-Rong Hou, Meng-Qi He
OBJECTIVE: To assess the value of Prostate Imaging and Reporting and Data System: Version 2 (PI-RADS v2) combined with prostate specific antigen (PSA) in the diagnosis of peripheral zone (PZ) prostate cancer (PCa). METHODS: The preoperative magnetic resonance imaging and PSA data were ananlyzed for 69 patients with pathologically confirmed PCa and 109 non-PCa patients. PI-RADS v2 scores (1-5) was used to evaluate the risk of PZ PCa. The total PSA (tPSA) level, free to total PSA ratio (f/t PSA), PSA density (PSAD), PZ-PSAD and PI-RADS v2 scores were compared between the PCa and non-PCa patients...
August 20, 2017: Nan Fang Yi Ke da Xue Xue Bao, Journal of Southern Medical University
https://www.readbyqxmd.com/read/28798822/an-assessment-of-prostate-cancer-research-international-active-surveillance-prias-criteria-for-active-surveillance-of-clinically-low-risk-prostate-cancer-patients
#14
Vitor da Silva, Ilias Cagiannos, Luke T Lavallée, Ranjeeta Mallick, Kelsey Witiuk, Sonya Cnossen, James A Eastham, Dean A Fergusson, Chris Morash, Rodney H Breau
INTRODUCTION: Active surveillance is a strategy to delay or prevent treatment of indolent prostate cancer. The Prostate Cancer Research International: Active Surveillance (PRIAS) criteria were developed to select patients for prostate cancer active surveillance. The objective of this study was to compare pathological findings from PRIAS-eligible and PRIAS-ineligible clinically low-risk prostate cancer patients. METHODS: A D'Amico low-risk cohort of 1512 radical prostatectomy patients treated at The Ottawa Hospital or Memorial Sloan Kettering Cancer Centre between January 1995 and December 2007 was reviewed...
August 2017: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/28791252/prostate-specific-antigen-5-years-following-stereotactic-body-radiation-therapy-for-low-and-intermediate-risk-prostate-cancer-an-ablative-procedure
#15
Shaan Kataria, Harsha Koneru, Shan Guleria, Malika Danner, Marilyn Ayoob, Thomas Yung, Siyuan Lei, Brian T Collins, Simeng Suy, John H Lynch, Thomas Kole, Sean P Collins
BACKGROUND: Our previous work on early PSA kinetics following prostate stereotactic body radiation therapy (SBRT) demonstrated that an initial rapid and then slow PSA decline may result in very low PSA nadirs. This retrospective study sought to evaluate the PSA nadir 5 years following SBRT for low- and intermediate-risk prostate cancer (PCa). METHODS: 65 low- and 80 intermediate-risk PCa patients were treated definitively with SBRT to 35-37.5 Gy in 5 fractions at Georgetown University Hospital between January 2008 and October 2011...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28781111/creation-and-internal-validation-of-a-biopsy-avoidance-prediction-tool-to-aid-in-the-choice-of-diagnostic-approach-in-patients-with-prostate-cancer-suspicion
#16
Bimal Bhindi, Haiyan Jiang, Cedric Poyet, Thomas Hermanns, Robert J Hamilton, Kathy Li, Ants Toi, Antonio Finelli, Alexandre R Zlotta, Theodorus H van der Kwast, Andrew Evans, Neil E Fleshner, Girish S Kulkarni
INTRODUCTION: To reduce unnecessary prostate biopsies while using novel tests judiciously, we created a tool to predict the probability of clinically significant prostate cancer (CSPC) vs. low-risk prostate cancer or negative biopsy (i.e., when intervention is likely not needed) among men undergoing initial or repeat biopsy. METHODS: Separate models were created for men undergoing initial and repeat biopsy, identified from our institutional biopsy database and the placebo arm of the REDUCE trial, respectively, to predict the presence of CSPC (Gleason≥7 or>33% of cores involved)...
August 3, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28780740/knowledge-attitudes-and-practices-towards-prostate-cancer-screening-amongst-men-living-in-the-southern-italian-peninsula-the-prevention-and-research-in-oncology-pro-non-profit-foundation-experience
#17
Vincenzo Mirone, Ciro Imbimbo, Davide Arcaniolo, Marco Franco, Roberto La Rocca, Luca Venturino, Lorenzo Spirito, Massimiliano Creta, Paolo Verze
PURPOSE: We aimed to explore the knowledge, attitudes, and practices towards prostate cancer (PCa) risk factors and prevention amongst men living in the southern Italian peninsula. METHODS: We retrospectively reviewed data collected during free preventive visits carried out by the Prevention and Research in Oncology (PRO) non-profit Foundation between July 2013 and July 2016. The following data were collected: demographic and clinical features, knowledge about PCa prevention and sources of knowledge, knowledge about PCa risk factors, previous prostate-specific antigen (PSA) test, previous digital rectal examination (DRE), previous prostate ultrasound, and general attitudes towards DRE...
August 5, 2017: World Journal of Urology
https://www.readbyqxmd.com/read/28779974/impact-of-early-salvage-radiation-therapy-in-patients-with-persistently-elevated-or-rising-prostate-specific-antigen-after-radical-prostatectomy
#18
Nicola Fossati, R Jeffrey Karnes, Michele Colicchia, Stephen A Boorjian, Alberto Bossi, Thomas Seisen, Nadia Di Muzio, Cesare Cozzarini, Barbara Noris Chiorda, Claudio Fiorino, Giorgio Gandaglia, Paolo Dell'Oglio, Shahrokh F Shariat, Gregor Goldner, Steven Joniau, Antonino Battaglia, Karin Haustermans, Gert De Meerleer, Valérie Fonteyne, Piet Ost, Hendrik Van Poppel, Thomas Wiegel, Francesco Montorsi, Alberto Briganti
BACKGROUND: Salvage radiation therapy (SRT) is a recommended treatment option for biochemical recurrence after radical prostatectomy (RP). However, its effectiveness may be limited to specific categories of patients. OBJECTIVE: We aimed to identify the optimal candidates for early SRT after RP. DESIGN, SETTING, AND PARTICIPANTS: The study included 925 node-negative patients treated with SRT after RP at seven institutions. Patients received SRT for either prostate-specific antigen (PSA) rising, or PSA persistence after RP that was defined as PSA level ≥0...
August 2, 2017: European Urology
https://www.readbyqxmd.com/read/28770408/phase-ii-study-of-radium-223-dichloride-in-japanese-patients-with-symptomatic-castration-resistant-prostate-cancer
#19
Nobuaki Matsubara, Satsohi Nagamori, Yoshiaki Wakumoto, Hirotsugu Uemura, Go Kimura, Akira Yokomizo, Hiroaki Kikukawa, Atsushi Mizokami, Takeo Kosaka, Naoya Masumori, Yoshihide Kawasaki, Junji Yonese, Yasutomo Nasu, Satoshi Fukasawa, Takayuki Sugiyama, Seigo Kinuya, Makoto Hosono, Iku Yamaguchi, Hirokazu Tsutsui, Hiroji Uemura
BACKGROUND: Radium-223 dichloride (radium-223) is the first targeted alpha therapy approved for the treatment of castration-resistant prostate cancer (CRPC) with bone metastases. This study investigated the efficacy and safety of radium-223 in Japanese patients with symptomatic CRPC and bone metastases. METHODS: In this open-label, multicenter, phase II study, patients with progressive, symptomatic CRPC and bone metastases were treated with radium-223 (55 kBq/kg, intravenously) in a 4-week cycle for six cycles...
August 2, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28765515/the-prognostic-implication-of-intraductal-carcinoma-of-the-prostate-in-metastatic-castration-resistant-prostate-cancer-and-its-potential-predictive-value-in-those-treated-with-docetaxel-or-abiraterone-as-first-line-therapy
#20
Jinge Zhao, Pengfei Shen, Guangxi Sun, Ni Chen, Jiandong Liu, Xin Tang, Rui Huang, Diming Cai, Jing Gong, Xingming Zhang, Zhibin Chen, Xiang Li, Qiang Wei, Peng Zhang, Zhenhua Liu, Jiyan Liu, Hao Zeng
Intraductal carcinoma of the prostate (IDC-P) is recognized as a newly pathological entity in 2016 WHO classification. It's role in metastatic castration-resistant prostate cancer (CRPC) remains obscure. We aimed to explore the association of IDC-P with clinical outcome and to further identify its potential predictive role in making first-line treatment decisions for mCRPC. We retrospectively analyzed data of 131 mCRPC patients. IDC-P was diagnosed by re-biopsy at the time of mCRPC. Among total patients, 45 and 41 received abiraterone or docetaxel as first-line therapies, respectively...
July 24, 2017: Oncotarget
keyword
keyword
25554
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"